Skip to main content
EHCEncompass Health CorporationHold6.1·$99.84+0.48%
Open full analysis

Encompass Health Corporation (EHC) Stock Analysis

HoldModerate Confidence

Healthcare · Medical Care Facilities

Hold if already holding. Not a fresh buy at $99.84, but acceptable to hold if already in. Reasons: Negative momentum; Below 200-MA, MA slope -1.5%/30d (confirmed downtrend).

Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals, operating 173 facilities across 39 states and Puerto Rico, with concentrations in Florida and Texas. The company generated $5.9 billion in net operating revenues in... Read more

$99.84+22.4% A.UpsideScore 6.1/10#4 of 27 Medical Care Facilities
QualityF-score7 / 9FCF yield2.88%
IncomeYield0.76%(5y avg 1.09%)Payout12.67%sustainable
Stop $95.37Target $122.23(analyst − 13%)A.R:R 3.6:1
Analyst target$140.50+40.7%12 analysts
$122.23our TP
$99.84price
$140.50mean
$152

Hold if already holding. Not a fresh buy at $99.84, but acceptable to hold if already in. Reasons: Negative momentum; Below 200-MA, MA slope -1.5%/30d (confirmed downtrend). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

10-K grounded · weekly refresh

About Encompass Health Corporation

About Encompass Health Corporation

Encompass Health Corporation operated 173 inpatient rehabilitation hospitals across 39 states and Puerto Rico at December 31, 2025, generating total net operating revenues of $5.9 billion — up from $5.4 billion in 2024 — and treating 263,299 patients through discharge. Concentrations in Florida and Texas reflect the company's strategy of expanding in high-growth demographic markets. The company has opened or acquired 78 new hospitals and increased licensed bed count by approximately 72% since 2012, and employed over 42,000 individuals at year-end.

Encompass Health earns revenue primarily through Medicare reimbursement under the inpatient rehabilitation facility prospective payment system, alongside Medicare Advantage, Medicaid, and commercial payors. Substantially all (92%) of patients are admitted from acute-care hospitals following physician referrals — a structure that makes the company dependent on relationships with referring hospitals and health systems. More than a third of hospitals operate as joint ventures with acute-care systems, creating referral alignment. The company competes against rehabilitation units within acute-care hospitals, privately held post-acute care providers, and one publicly traded company operating 38 inpatient rehabilitation hospitals. The target patient demographic is concentrated in Medicare beneficiaries aged 65 and older, where the population of age 75 and over is expected to grow at approximately 4% per year through 2030, providing long-term demand growth.

Show full overview

Medicare reimbursement risk is the dominant regulatory exposure. The 10-K identifies restrictive coverage determinations by Medicare Advantage plans during pre-authorization as a material threat to revenues, while also noting that changes in payment system re-basing or the introduction of value-based models could reduce revenues if not offset by demonstrated outcome superiority. The company has pursued improvement in MA payments by demonstrating higher discharge-to-community rates and lower lengths of stay versus alternative care sites. If CMS re-bases the IRF payment system or reduces rates, Encompass Health's revenues and operating margins could be materially affected.

See also: Healthcare · Medical Care Facilities

From Encompass Health Corporation's most recent 10-K filing, extracted June 10, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-17
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Aug 4, 202649d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
Attractive valuation
Analyst upside: 22%
Risks
Negative momentum
Below 200-MA, MA slope -1.5%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)17.0
P/E (Fwd)15.2
Mkt Cap$9.9B
EV/EBITDA9.4
Profit Mgn10.0%
ROE25.2%
Rev Growth9.0%
Beta0.59
Dividend0.76%
Rating analysts17

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.20bullish
IV48%normal
Max Pain$155+55.2% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMGeographicFlorida and Texas
    10-K Item 1: 'We operate hospitals in 39 states and Puerto Rico, with concentrations in Florida and Texas.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
1.0
Rsi
4.5
Volume
6.4
Volume distribution (falling OBV)Below 200-MA, MA slope -1.5%/30d — confirmed downtrend
GatesMomentum 2.6<4.5Death cross (50MA < 200MA)A.R:R 3.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 49d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
42 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $98.32Resistance $106.92

Price Targets

$95
$122
A.Upside+22.4%
A.R:R3.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 2.6 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-04 (49d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is EHC stock a buy right now?

Hold if already holding. Not a fresh buy at $99.84, but acceptable to hold if already in. Reasons: Negative momentum; Below 200-MA, MA slope -1.5%/30d (confirmed downtrend). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $122.23 (+22.4%), stop $95.37 (−4.7%), A.R:R 3.6:1. Score 6.1/10, moderate confidence.

What is the EHC stock price target?

Take-profit target: $122.23 (+22.4% upside). Target $122.23 (+22.4%), stop $95.37 (−4.7%), A.R:R 3.6:1. Stop-loss: $95.37.

What are the risks of investing in EHC?

Negative momentum; Below 200-MA, MA slope -1.5%/30d (confirmed downtrend).

Is EHC overvalued or undervalued?

Encompass Health Corporation trades at a P/E of 17.0 (forward 15.2). TrendMatrix value score: 8.1/10. Verdict: Hold.

What do analysts say about EHC?

17 analysts cover EHC with a consensus score of 4.4/5. Average price target: $141.

What does Encompass Health Corporation do?Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals,...

Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals, operating 173 facilities across 39 states and Puerto Rico, with concentrations in Florida and Texas. The company generated $5.9 billion in net operating revenues in 2025, earning revenue primarily from Medicare, Medicare Advantage, Medicaid, and commercial payors, with 92% of patients admitted from acute-care hospitals following physician referrals.

Related stocks: AVAH (Aveanna Healthcare Holdings Inc) · THC (Tenet Healthcare Corporation) · UHS (Universal Health Services, Inc.) · ARDT (Ardent Health, Inc.) · ASTH (Astrana Health Inc.)
Home Stocks EHC

Latest news

Latest News

Yahoo Finance49d agoEarnings
GuruFocus56d ago
Yahoo Finance42d ago
MSN50d ago
AlphaStreet50d agoEarnings
Yahoo Finance50d ago
Newser22d ago
MarketBeat57d ago
Yahoo Finance47d ago
Quiver Quantitative47d ago
StockStory47d agoEarnings
Marketscreener.com48d agoEarnings
MSN48d ago
Yahoo Finance20d ago
Investing.com Nigeria20d agoAnalyst
Yahoo Finance55d agoEarnings
MSN26d ago
Florida Hospital News and Healthcare Report41d ago
TradingView41d agoEarnings
Yahoo Finance45d ago
Loading more...